130 related articles for article (PubMed ID: 20854761)
1. Assessing cancer drugs for reimbursement: methodology, relationship between effect size and medical need.
de Sahb-Berkovitch R; Woronoff-Lemsi MC; Molimard M;
Therapie; 2010; 65(4):373-7, 367-72. PubMed ID: 20854761
[TBL] [Abstract][Full Text] [Related]
2. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
3. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
Enzmann H; Broich K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
[TBL] [Abstract][Full Text] [Related]
4. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
5. Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
Drummond M; Evans B; LeLorier J; Karakiewicz P; Martin D; Tugwell P; MacLeod S
Can J Clin Pharmacol; 2009; 16(2):e273-81; discussion e282-4. PubMed ID: 19439771
[TBL] [Abstract][Full Text] [Related]
6. "Just Another Statistic".
Machtay M; Glatstein E
Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
[TBL] [Abstract][Full Text] [Related]
7. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
8. Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy.
Zhuang SH; Xiu L; Elsayed YA
Cancer J; 2009; 15(5):395-400. PubMed ID: 19826359
[TBL] [Abstract][Full Text] [Related]
9. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials.
Driscoll JJ; Rixe O
Cancer J; 2009; 15(5):401-5. PubMed ID: 19826360
[TBL] [Abstract][Full Text] [Related]
10. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
Wilkerson J; Fojo T
Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of the medical value of a drug. A necessity for the Transparency Commission].
Avouac B
Therapie; 1992; 47(1):9-16. PubMed ID: 1523604
[TBL] [Abstract][Full Text] [Related]
12. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
13. Comparators (medicinal and non medicinal) for marketing authorization, for public health, for payers and at the European level.
Berdaï D; Hotton JM; Lechat P;
Therapie; 2010; 65(4):329-34. PubMed ID: 20854755
[TBL] [Abstract][Full Text] [Related]
14. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
15. Real medical benefit assessed by indirect comparison.
Falissard B; Zylberman M; Cucherat M; Izard V; Meyer F
Therapie; 2009; 64(3):225-32. PubMed ID: 19671436
[TBL] [Abstract][Full Text] [Related]
16. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.
Lebwohl D; Kay A; Berg W; Baladi JF; Zheng J
Cancer J; 2009; 15(5):386-94. PubMed ID: 19826358
[TBL] [Abstract][Full Text] [Related]
17. [Drug evaluation by the French National Health Authority for reimbursement decisions].
Bouvenot G
Bull Acad Natl Med; 2005 Nov; 189(8):1683-90; discussion 1690-1. PubMed ID: 16737094
[TBL] [Abstract][Full Text] [Related]
18. [Access to medicines in France].
Bouvenot G; Bouvenot J
Bull Acad Natl Med; 2009 Mar; 193(3):649-59; discussion 659-62. PubMed ID: 19883016
[TBL] [Abstract][Full Text] [Related]
19. Endpoints for assessing drug activity in clinical trials.
Pazdur R
Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
